In the Viewpoint “Deciphering Cholesterol Treatment Guidelines: A Clinician’s Perspective” published in the March 10, 2015, issue of JAMA,1 and in the subsequent reply letter entitled “Clinician Understanding of Cholesterol Treatment Guidelines” published in the June 16, 2015, issue of JAMA,2 the author neglected to cite conflict of interest disclosures. Dr Ganda reports receiving research funding from Amarin Pharmaceuticals, consulting fees from Amgen and Sanofi, and speaker’s honoraria from Janssen and Merck. These articles were corrected online.
Omitted Financial Disclosures. JAMA. 2015;314(13):1404. doi:10.1001/jama.2015.11728